Abstract: Transgenic soybean seed having increased total fatty acid content of at least 20% and altered fatty acid profiles when compared to the total fatty acid content of non-transgenic, null segregant soybean seed are described. DGAT genes from Yarrowia lipolytica combined with plastidic phosphoglucomutase down regulation are used to achieve the increase in seed storage lipids.

Abstract: Transgenic soybean seed having increased total fatty acid content of at least 10% and altered fatty acid profiles when compared to the total fatty acid content of non-transgenic, null segregant soybean seed are described. DGAT genes from oleaginous organisms are used to achieve the increase in seed storage lipids.

Abstract: Recombinant constructs useful for reducing the expression of endogenous mRNA and any substantially similar endogenous mRNA are disclosed. In particular, a recombinant construct comprising, inter alia, a suitable nucleic acid sequence and its reverse complement can be used to alter the expression of any homologous, endogenous RNA (i.e., the target RNA) which is in proximity to this suitable nucleic acid sequence.

Abstract: Compositions and methods related to transgenic high oleic acid/ALS inhibitor-tolerant soybean plants are provided. Specifically, the present invention provides soybean plants having a DP-305423-1 event which imparts a high oleic acid phenotype and tolerance to at least one ALS-inhibiting herbicide. The soybean plant harboring the DP-305423-1 event comprises genomic/transgene junctions having at least the polynucleotide sequence of SEQ ID NO:8, 9, 14, 15, 20, 21, 83 or 84. The characterization of the genomic insertion site of the DP-305423-1 event provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the soybean DP-305423-1 events are provided.

Abstract: Recombinant constructs useful for reducing the expression of endogenous mRNA and any substantially similar endogenous mRNA are disclosed. In particular, a recombinant construct comprising, inter alia, a suitable nucleic acid sequence and its reverse complement can be used to alter the expression of any homologous, endogenous RNA (i.e., the target RNA) which is in proximity to this suitable nucleic acid sequence.

Abstract: This invention relates to an isolated nucleic acid fragment encoding a cholinephosphate cytidylyltransferase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the cholinephosphate cytidylyltransferase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the cholinephosphate cytidylyltransferase in a transformed host cell.

Abstract: This invention relates to an isolated nucleic acid fragment encoding a cholinephosphate cytidylyltransferase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the cholinephosphate cytidylyltransferase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the cholinephosphate cytidylyltransferase in a transformed host cell.

Abstract: This invention relates to an isolated nucleic acid fragment encoding a cholinephosphate cytidylyltransferase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the cholinephosphate cytidylyltransferase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the cholinephosphate cytidylyltransferase in a transformed host cell.

Abstract: Recombinant constructs useful for reducing the expression of endogenous mRNA and any substantially similar endogenous mRNA are disclosed. In particular, a recombinant construct comprising, inter alia, a suitable nucleic acid sequence and its reverse complement can be used to alter the expression of any homologous, endogenous RNA (i.e., the target RNA) which is in proximity to this suitable nucleic acid sequence.